Medications

Two clinically studied options for medically supervised weight loss

Compounded semaglutide and tirzepatide — the same active ingredients behind the most studied weight loss medications of the last decade, prepared by a state-licensed compounding pharmacy.

Semaglutide Tirzepatide
Important disclosure: Compounded medications are prepared by state-licensed compounding pharmacies and are not FDA-approved products. They are not the same as commercially manufactured brand-name drugs. Clinical data referenced on this page is for the active pharmaceutical ingredient, not the compounded formulation specifically. A valid prescription is required for all medications.
How They Work

The science behind GLP-1 medications

GLP-1 (glucagon-like peptide-1) is a hormone naturally released by your gut after eating. These medications mimic that hormone — at therapeutic levels — to produce meaningful, sustained weight loss.

🧠

Appetite Suppression

GLP-1 receptors in the brain (hypothalamus) receive signals that reduce hunger and cravings. Most patients report eating significantly less without feeling deprived.

⏱️

Slows Gastric Emptying

Food moves more slowly from the stomach to the small intestine, extending the feeling of fullness after meals and reducing the drive to snack between meals.

🩸

Blood Sugar Regulation

These medications stimulate insulin release in response to meals and suppress glucagon. This helps stabilize blood sugar — especially relevant for patients with type 2 diabetes or pre-diabetes.

Compounded injectable medication vials and syringe
Option 1

Compounded Semaglutide

Semaglutide is a GLP-1 receptor agonist. The active ingredient in semaglutide was studied in the landmark STEP-1 trial (published in NEJM, 2021) — participants on the highest dose lost an average of 14.9% of their body weight over 68 weeks.

Compounded semaglutide uses the same active pharmaceutical ingredient, prepared by a state-licensed compounding pharmacy. It is not FDA-approved and is not equivalent to commercially manufactured semaglutide products.

Starting at $249/month
💉

Once-Weekly Injection

Subcutaneous self-injection in the abdomen, thigh, or upper arm.

📈

Gradual Titration

Starts at 0.25mg/week, increases over 16+ weeks to 2.4mg maintenance.

📦

Ships Monthly

Multi-dose vial with syringes and supplies included every month.

👨‍⚕️

Provider Check-Ins

Monthly clinical review, dose adjustments, and ongoing support.

Get Started See Pricing

Standard Titration Schedule

WeeksDosePhaseMonthly Price
1–40.25 mg/weekInitiation$249/mo
5–80.5 mg/weekTitration$249/mo
9–121.0 mg/weekTitration$299/mo
13–161.7 mg/weekTitration$329/mo
17+2.4 mg/weekMaintenance$349/mo

Your prescriber may adjust this schedule based on tolerability and response. Dose increases are not automatic — they require provider approval at each monthly check-in.

Published Trial Data — Active Ingredient
14.9%
Avg body weight reduction at 68 weeks (STEP-1)
86%
Achieved >5% body weight loss
69%
Achieved >10% body weight loss

Data from STEP-1 (Wilding et al., NEJM 2021). Published clinical trial results for the active pharmaceutical ingredient semaglutide 2.4mg. Compounded semaglutide is not FDA-approved and clinical outcomes may differ. Individual results will vary.

Medical treatment and clinical care
Option 2

Compounded Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist. By activating both the GIP and GLP-1 receptors simultaneously, tirzepatide has produced the largest average weight loss of any approved medication to date.

The SURMOUNT-1 trial (published in NEJM, 2022) showed an average of 20.9% body weight reduction over 72 weeks at the highest dose. Compounded tirzepatide uses the same active ingredient, prepared by a state-licensed compounding pharmacy. Not FDA-approved.

Starting at $349/month
💉

Once-Weekly Injection

Same administration method as semaglutide — subcutaneous self-injection.

📈

Gradual Titration

Starts at 2.5mg/week, increases every 4 weeks to a maximum of 15mg.

⚡

Dual Mechanism

Activates both GIP and GLP-1 receptors — distinct from semaglutide's single-receptor action.

👨‍⚕️

Provider Check-Ins

Monthly clinical reviews and dose management included.

Get Started See Pricing

Standard Titration Schedule

WeeksDosePhaseMonthly Price
1–42.5 mg/weekInitiation$349/mo
5–85.0 mg/weekTitration$399/mo
9–127.5 mg/weekTitration$449/mo
13–1610.0 mg/weekTitration$499/mo
17–2012.5 mg/weekTitration$499/mo
21+15.0 mg/weekMaintenance$499/mo

Dose progression requires provider approval at each monthly check-in. Your provider may slow titration if side effects are significant.

Published Trial Data — Active Ingredient
20.9%
Avg body weight reduction at 72 weeks (SURMOUNT-1, 15mg)
91%
Achieved >5% body weight loss
57%
Achieved >20% body weight loss

Data from SURMOUNT-1 (Jastreboff et al., NEJM 2022). Published clinical trial results for the active pharmaceutical ingredient tirzepatide 15mg. Compounded tirzepatide is not FDA-approved and clinical outcomes may differ. Individual results will vary.

Side by Side

Which medication is right for you?

Your prescriber will make this determination based on your individual health profile. Here's how the two options compare.

Compounded Semaglutide Compounded Tirzepatide
MechanismGLP-1 receptor agonistDual GIP + GLP-1 agonist
Injection frequencyOnce weeklyOnce weekly
Starting dose0.25 mg/week2.5 mg/week
Max dose2.4 mg/week15.0 mg/week
Avg weight loss (trial data)~14.9% at 68 weeks~20.9% at 72 weeks
Starting monthly price$249/mo$349/mo
Max monthly price$349/mo$499/mo

Clinical trial data is for the FDA-approved active ingredient, not compounded formulations. Individual results will vary significantly.

Not sure which is right for you? Your prescriber will recommend the appropriate option after reviewing your intake.

Start Your Intake
Safety

What you need to know before starting

⚠️

Do Not Use If

  • Personal/family history of MTC thyroid cancer
  • History of MEN2
  • Pregnant or planning pregnancy
  • Breastfeeding
  • Known hypersensitivity to the ingredient
💊

Common Side Effects

  • Nausea (especially early in titration)
  • Vomiting, diarrhea, constipation
  • Decreased appetite
  • Injection site reactions
  • Headache, fatigue
Read Full Safety Information →